SF-295 Xenograft Model Service for Glioblastoma

The SF-295 xenograft model represents a well-characterized preclinical platform for glioblastoma multiforme (GBM) research, enabling robust evaluation of therapeutic efficacy, tumor growth kinetics, and molecular response mechanisms in vivo. Alfa Cytology delivers comprehensive, GLP-compliant SF-295 xenograft model services tailored to your drug discovery pipeline---from cell line authentication and tumor implantation to longitudinal monitoring, histopathological analysis, and biomarker profiling---ensuring reproducible, publication-ready data for your preclinical oncology programs.

Overview of SF-295 Xenograft Model for Glioblastoma

The SF-295 cell line was established in the late 1980s from a left frontal lobe tumor specimen of a 67-year-old Caucasian female patient diagnosed with glioblastoma multiforme (GBM). As a member of the National Cancer Institute (NCI-60) panel, SF-295 has served as a foundational model for high-throughput drug screening and mechanistic studies in neuro-oncology. The cell line exhibits a hypertriploid karyotype with a modal chromosome number of 118 (range 104--126) and carries hallmark GBM mutations, including homozygous inactivation of PTEN and TP53, along with the TERT promoter C228T mutation. Notably, SF-295 cells display glial-like morphology in vitro but lack expression of typical astrocytic markers GFAP and glutamine synthetase, while retaining neurofibromin-1 (NF1) expression. In xenograft settings, SF-295 demonstrates non-tumorigenic behavior in nude mice when implanted orthotopically, yet forms measurable subcutaneous tumors in immunocompromised hosts, making it particularly valuable for pharmacodynamic and toxicity assessments.

Preclinical studies utilizing the SF-295 xenograft model have contributed significantly to glioblastoma therapeutic development. Plowman et al. (1994) demonstrated synergistic antitumor activity between temozolomide (TMZ) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU, carmustine) in SF-295 xenografts, achieving equivalent efficacy with reduced toxicity compared to monotherapy. More recently, SF-295 has been employed to evaluate novel agents targeting DNA repair pathways, angiogenesis inhibitors, and metabolic modulators. The model's defined molecular background---particularly its PTEN/TP53-null status---makes it an ideal substrate for testing PI3K/AKT pathway inhibitors, DNA damage response modulators, and combination regimens aimed at overcoming chemoresistance in GBM. Researchers have also utilized SF-295 to study telomerase biology, as the cell line harbors recurrent TERT promoter mutations characteristic of primary GBM, providing insights into mechanisms of cellular immortalization and potential therapeutic vulnerabilities.

Figure 1. Sensitive SF-295 glioma and resistant A549 lung cancer cells have different gene expression profiles. (Weissenrieder, J. S., et al., 2022)

Cell Line Information: SF-295

The SF-295 cell line is extensively characterized and widely distributed through international cell line repositories. Below is a comprehensive summary of its biological and genetic attributes:

Our Services

Alfa Cytology specializes in the development and execution of clinically relevant preclinical xenograft models, including the SF-295 glioblastoma platform. Our integrated service portfolio encompasses cell line authentication via STR profiling, tumor implantation and monitoring, therapeutic administration, tumor volume quantification, histopathological evaluation, and biomarker analysis---delivering rigorous, reproducible datasets to accelerate your oncology drug development from lead optimization to IND-enabling studies. With expertise in both subcutaneous and orthotopic implantation techniques, we provide customized study designs aligned with your compound mechanism and regulatory requirements.

Workflow of SF-295 Xenograft Model Construction

Construction of the SF-295 xenograft model follows a standardized, quality-controlled workflow optimized for reproducible tumor engraftment and longitudinal therapeutic assessment. The process integrates cell line validation, animal preparation, tumor cell implantation, postoperative monitoring, and endpoint analysis to ensure robust preclinical data generation.

1. Cell Line Authentication and Expansion: SF-295 cells are authenticated via short tandem repeat (STR) profiling and verified for mycoplasma negativity. Cells are expanded under standard culture conditions (RPMI 1640 + 10% FBS, 37 degrees C, 5% CO2) to log-phase growth, harvested using trypsin-EDTA, and resuspended in serum-free medium at optimal concentration (typically 1x10^6 to 5x10^6 cells per 100--200 uL) for implantation.
2. Animal Model Selection and Preparation: Immunocompromised mice (commonly BALB/c nude or NOD/SCID strains, 6--8 weeks old) are acclimatized under pathogen-free conditions. Animals are randomized by body weight and ear-tagged for individual identification. Baseline health assessments and body weight recordings are performed prior to tumor cell injection.
3. Tumor Cell Implantation: For subcutaneous models, SF-295 cell suspensions are injected into the right flank using a 25-gauge needle. For orthotopic intracranial models, stereotactic injection into the striatum (coordinates: 2 mm lateral, 1 mm anterior to bregma, 3 mm depth) is performed under general anesthesia. Tumor cells are mixed with Matrigel (1:1 ratio) to enhance engraftment consistency.
4. Postoperative Monitoring and Tumor Growth Assessment: Animals are monitored daily for neurological signs, body weight, and general health status. Subcutaneous tumor dimensions are measured twice weekly using digital calipers, and tumor volume is calculated via the modified ellipsoid formula (V = 0.5 x length x width^2). Orthotopic tumor progression is monitored via bioluminescence imaging (for luciferase-expressing lines) or MRI.
5. Therapeutic Intervention: Upon reaching predetermined tumor volume (typically 100--200 mm^3 for subcutaneous models), animals are randomized into treatment cohorts. Test compounds are administered according to the study design (dosing route, frequency, and duration). Tumor dimensions and body weights are recorded throughout the study. At termination, tumors are excised, weighed, and processed for histology, biomarker analysis, and molecular profiling.
6. Histopathological and Molecular Characterization: Tumor sections are stained with H&E for morphological assessment and subjected to immunohistochemistry (IHC) for Ki-67, CD31, cleaved caspase-3, and target-specific markers. Western blot and qPCR analyses are performed on frozen tissue to evaluate pathway modulation and drug target engagement.

Figure 2. SF-295 xenograft model construction workflow.

Case Study-SF-295 Xenograft Model Development

Alfa Cytology has successfully established and validated the SF-295 subcutaneous xenograft model for preclinical evaluation of novel GBM therapeutics. In a representative study, SF-295 cells were implanted into immunocompromised mice and allowed to establish palpable tumors over a 14--21 day period. Upon reaching target tumor volumes, animals were treated with investigational compounds targeting the PI3K/AKT/mTOR pathway. Longitudinal monitoring demonstrated dose-dependent tumor growth inhibition, with treated cohorts showing significant reductions in tumor volume compared to vehicle controls. Comprehensive endpoint analysis revealed decreased Ki-67 proliferation index, increased apoptotic markers, and modulation of downstream signaling targets as confirmed by IHC and Western blot. Detailed quantitative data, including tumor growth curves, survival analysis, and pharmacodynamic biomarker results, are available upon request through our scientific team.

Why Choose Alfa Cytology?

Alfa Cytology provides end-to-end preclinical oncology services with rigorous quality standards and scientific expertise. Our SF-295 xenograft model service offers distinct advantages for your drug development program:

• Fully authenticated SF-295 cell lines with verified STR profiles and mycoplasma-free certification ensure reproducible study initiation.
• Flexible implantation options including subcutaneous and orthotopic stereotactic models tailored to your therapeutic mechanism and endpoint requirements.
• Real-time tumor monitoring capabilities via digital caliper measurement, bioluminescence imaging, and small-animal MRI for precise growth kinetic assessment.
• Comprehensive histopathology and molecular analysis services including IHC, Western blot, qPCR, and multiplex cytokine profiling from a single study platform.
• GLP-compliant study documentation and data packages designed to support IND submissions and peer-reviewed publications.
• Dedicated project management with PhD-level scientific oversight ensuring protocol customization, proactive troubleshooting, and timely delivery of results.

Contact Us

Accelerate your glioblastoma therapeutic development with Alfa Cytology's validated SF-295 xenograft model service. Whether you require standard subcutaneous implantation, orthotopic stereotactic models, or customized combination therapy studies, our scientific team is ready to design a study protocol aligned with your research objectives. Please reach out to us today via our inquiry form or email to learn more about our SF-295 Xenograft Model services.

For research use only. Not intended for any clinical use.